期刊文献+

26S蛋白酶体组装的分子机制研究 被引量:1

Molecular Mechanisms of the Assembly of 26S Proteasome
原文传递
导出
摘要 26S蛋白酶体广泛分布于真核细胞中的胞质和胞核,主要是由20S核心复合物(coreparticle,CP)和19S调节复合物(regulatory particle,RP)组成,它负责细胞大多数蛋白质的降解,在几乎所有生命活动中具有关键的调控作用。26S蛋白酶体的组装是一个非常复杂且高度条理的过程,不同的分子伴侣,如PAC1-4、Ump1、p27、p28和s5b等,参与其中发挥识别及调节作用,以确保高效准确地完成蛋白酶体的组装。本文系统总结分析了20S核心复合物和19S调节复合物的组装过程及调控机制的最近研究进展。 The 26S proteasome is composed of one 20S catalytic core particle and one or two 19S regulatory particles,it is widely distributed in the nucleus and cytoplasm of eukaryotic cell.The 26S proteasome is responsible for degradation of most ubiquitylated proteins in the cell,playing critical regulatory roles in nearly all the biological processes.The assembly of 26S proteasome is a complicated and highly coordinated process,assembly of 20S CP and 19S RP is accompanied by several proteasome-dedicated chaperons,including PAC1-4,Ump1,p27,p28,s5b and so on.These chaperons function as crucial adaptors for efficient and accurate proteasome assembly.In this review,we summarize recent advances in the multistep assembly process and regulatory mechanisms of 26S proteasome.
出处 《生物物理学报》 CAS CSCD 北大核心 2012年第6期441-447,共7页 Acta Biophysica Sinica
基金 国家自然科学基金项目(30970601 31125010)~~
关键词 26S蛋白酶体 20S核心复合物 19S调节复合物 组装 26S proteasome 20S core particle 19S regulatory particle Assembly
  • 相关文献

参考文献4

二级参考文献18

共引文献16

同被引文献19

  • 1Groll M, Kim K B, Kairies N, et al. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of , β -epoxyketone proteasome inhibitors[J]. JAm Chem Soc, 2000, 122: 1237-1238.
  • 2Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats[J]. Drug Metab Dispos, 2011, 39: 1873-1882.
  • 3FDA. Carfilzomib [EB/OL]. [2012-10-08]. http: // www. accessdata, fda. gov/drugsatfda_docs/label/2012/ 2027141bl. pdf.
  • 4Alsina M, Trudel S, Furman R R, et al. A phase I single- agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma[J]. Clin Cane Res, 2012, 18(17): 4830-4840.
  • 5Kuhn D J, Chen Q, Voorhees P M, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin- proteasome pathway, against preclinical models of multiple myeloma[J]. Blood, 2007, 110(9): 3281-3290.
  • 6Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats[J]. Drug Metab Disp, 2011, 39(10): 1873-1882.
  • 7O'Connor O A, Stewart A K, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies[J]. Clin Canc Res,2009, 15(22): 7085-7091.
  • 8Badros A Z, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharrnacokinetics and safety[J]. Leukemia, 2013, 27(8): 1707-1714.
  • 9Wang Z, Yang J, Kirk C, et al. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib[J]. Drug Metab Disp, 2013, 41(1): 230-237.
  • 10Redic K. Carfilzomib: a novel agent for multiple myeloma[J]. J Pharm Pharmacol, 2013, 65(8): 1095-1106.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部